Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | HTR1D | P28221 | 4/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | HTR1B | P28222 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7586102 | 0.85 | CYP2C19 (0.34) | CYP1A2CYP2C19HTR1DCA1CA2 | |
| SCHEMBL8119764 | 0.84 | CYP2C19 (0.38) | CYP1A2CYP2C19HTR1DCA1CA2 | |
| SCHEMBL7592443 | 0.79 | CA1 (0.40) | CA1CA2CA9KDM4EATM | |
| SCHEMBL8113705 | 0.78 | KLF10 (0.39) | CYP1A2CYP2C19HTR1DCA1CA2 | |
| SCHEMBL6760798 | 0.78 | CYP2C19 (0.38) | CYP1A2CYP2C19HTR1DCA1CA2 | |
| SCHEMBL4266306 | 0.77 | NPSR1 (0.51) | CYP2C19 | |
| SCHEMBL7999289 | 0.77 | NPSR1 (0.40) | CYP1A2CYP2C19HTR1DCA1CA2 | |
| SCHEMBL4261597 | 0.76 | TP53 (0.41) | CYP2C19HTR1DCA1CA2CA9 | |
| SCHEMBL7535667 | 0.75 | NPSR1 (0.38) | CYP2C19 | |
| SCHEMBL305273 | 0.73 | CYP4F2 (0.44) | CYP1A2CYP2C19KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7498460-B2 | Isophthalic acid derivatives | BAYER HEALTHCARE AG (DE) | 2009-03-03 | — | — | US | disclosed |
| EP-1572628-B1 | ISOPHTALIC ACID DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2007-07-25 | — | — | EP | disclosed |
| US-20060154912-A1 | Isophtalic acid derivatives | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-07-13 | — | — | US | disclosed |
| EP-1572628-A1 | ISOPHTALIC ACID DERIVATIVES | Bayer HealthCare AG (DE) | 2005-09-14 | — | — | EP | disclosed |
| WO-2004052839-A1 | ISOPHTALIC ACID DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154912-A1 | Isophtalic acid derivatives | VHL, FABP3, CPT1A | CYP1A2 96/4885CYP2C19 328/4885HTR1D 2426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.